BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Eric Linsley offers perspective on personalized medicine’s development
News | 03. 06. 2012
Eric Linsley offered his perspective on personalized medicine’s development during a symposium for PMC's recent report, The Case for Personalized Medicine. Linsley joined Jennie Hunter-Cevera, Ph.D., Executive Vice President, RTI International; Jonathan Roy, Senior Director and Head of Commercial Diagnostics for GlaxoSmithKline; Amy Abernethy, M.D., Director, Cancer Care Research Program at Duke University and David King, CEO of the Laboratory Corporation of America.
The Personalized Medicine Coalition latest newsletter summarizes these perspectives.
